Table 4.
Guideline recommendations for SGLT2i and ARNI for the Treatment of Heart Failure.
| HF category | SGLT2i |
ARNI |
||
|---|---|---|---|---|
| Recommendations of ACC/AHA guidelinesa | Recommendation of ESC guidelinesb | Recommendations of ACC/AHA guidelinesa | Recommendation of ESC guidelinesb | |
| HFrEF (LVEF ≤40 %) | 1 | 1 | 1 | 1 |
| HFmrEF (LVEF 41–49 %) | 2a | 1 | 2b | 2b |
| HFpEF (LVEF≥50 %) | 2a | 1 | 2b | Currently no recommendations |
| HFimpEF (previously LVEF ≤40 % now EF>40 %) | 1 (Continue and optimize GDMT) | Currently no recommendations | 1 (Continue and optimize GDMT) | Currently no recommendations |
Note:- HF: heart failure; HFrEF: Heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFmrEF: heart failure with mildly reduced ejection fraction; HFimpEF: heart failure with improved ejection fraction; SGLT2i: sodium-glucose co-transporter 2 inhibitor, ARNI: angiotensin receptor-neprilysin inhibitor, GDMT: guideline-directed medical therapy.
2022 AHA (American Heart Association)/ACC (American College of Cardiology)/HFSA (Heart Failure Society of America) Guideline for the Management of Heart Failure.
2023 Focused Update of the 2021 ESC (European Society of Cardiology) Guidelines for the diagnosis and treatment of acute and chronic heart failure.